This indication stems from cumulative evidence demonstrating their advantageous impact on decreasing HF-related hospitalizations and cardiovascular mortality rates [34], thereby establishing a novel foundational role for SGLT-2 inhibitors in HF management. The gene discussed is SLC5A2; the disease is hydrops fetalis.